Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Select Advanced Solid Tumors

In brief

IMC-C103C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen MAGE-A4. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for MAGE-A4.

Key facts

Study ID

NCT03973333

Run by

Immunocore Ltd

People needed

0

Starts

2019-05-17

Expected to finish

2023-09-25

Last updated by the study team

2024-10-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HLA-A*02:01 positive
• MAGE-A4 positive tumor
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) [ECOG PS] 0 or 1
• Selected advanced solid tumors
• Relapsed from, refractory to, or intolerant of standard therapy
• Measurable disease per RECIST v1.1 (expansion)
• If applicable, must agree to use highly effective contraception

You may not qualify if…

• Symptomatic or untreated central nervous system metastasis
• Inadequate washout from prior anticancer therapy
• Significant ongoing toxicity from prior anticancer treatment
• Impaired baseline organ function as evaluated by out-of-range laboratory values
• Clinically significant cardiac disease
• Active infection requiring systemic antibiotic therapy
• Known history of human immunodeficiency virus (HIV)
• Active hepatitis B virus (HBV) or hepatitis C virus (HCV)
• Ongoing treatment with systemic steroids or other immunosuppressive therapies
• Significant secondary malignancy
• Pregnancy or lactation

Where it is running

• The Angeles Clinic and Research Institute — Los Angeles, California, United States
• University of California Davis Comprehenvise Cancer Center — Sacramento, California, United States
• University of Colorado Cancer Center — Aurora, Colorado, United States
• The University of Chicago Medicine & Biological Sciences — Chicago, Illinois, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Oklahoma University Medical Center — Oklahoma City, Oklahoma, United States
• Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States
• UPMC Cancer Center — Pittsburgh, Pennsylvania, United States
• Sarah Cannon Research Institute at Tennessee Oncology — Nashville, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Hospital Universitario Vall d'Hebron — Barcelona, Spain
• Clinica Universidad Navarra — Madrid, Spain
• Hospital Universitario La Paz - PPDS — Madrid, Spain
• Clinica Universidad Navarra — Pamplona, Spain
• Beatson West of Scotland Cancer Centre — Glasgow, Scotland, United Kingdom
• The Clatterbridge Hospital Cancer Center — Bebington, United Kingdom
• Sarah Cannon Research Institute — London, United Kingdom
• The Christie NHS Foundation Trust — Manchester, United Kingdom
• Royal Marsden Hospital — Sutton, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.